Abstract | BACKGROUND: METHOD: A total of 50 with two combined therapeutic regimens treatment ineffective patients were evaluated. Patients were single blinded and randomly assigned to one of two medication groups that received the following regimens for 4 weeks: Group A (n = 30), combination of LRA, H1 antihistamine and H2 antihistamine. Group B (n = 20) continued with the previously taken two combination regimens. The treatment efficacy was measured by daily urticaria activity score (UAS) of wheal and itch. A positive therapeutic response was defined as a reduction to <25% of baseline weekly UAS, while a relapse was a return to >75% of baseline weekly UAS. RESULTS: At the end of 4 weeks, the UAS response to treatment of Group A was decreased from 35.2% to 21.2%, and the Group B was persisted with 33.9% as before the treatment. CONCLUSION: The combination of LRA, H2 antihistamine and H1 antihistamine is promising for the refractory CIU cases, which were refractory for two combined therapeutic regimens.
|
Authors | Kong-Sang Wan, Yung-Sen Chang |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 25
Issue 6
Pg. 459-61
(Dec 2014)
ISSN: 1471-1753 [Electronic] England |
PMID | 24192062
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine H2 Antagonists
- Leukotriene Antagonists
|
Topics |
- Adult
- Anti-Allergic Agents
(therapeutic use)
- Chronic Disease
- Drug Therapy, Combination
- Female
- Histamine H1 Antagonists
(therapeutic use)
- Histamine H2 Antagonists
(therapeutic use)
- Humans
- Leukotriene Antagonists
(therapeutic use)
- Male
- Middle Aged
- Single-Blind Method
- Treatment Outcome
- Urticaria
(drug therapy)
- Young Adult
|